BTR Capital Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $15.8M | Buy |
360,859
+8,640
| +2% | +$420K | 2.46% | 13 |
|
|
2022
Q2 | $18.5M | Sell |
352,219
-1,175
| -0.3% | -$59.9K | 2.65% | 10 |
|
|
2022
Q1 | $18.3M | Buy |
353,394
+82
| +0% | +$4.25K | 2.25% | 17 |
|
|
2021
Q4 | $20.9M | Buy |
353,312
+2,034
| +0.6% | +$101K | 2.35% | 14 |
|
|
2021
Q3 | $15.1M | Buy |
351,278
+459
| +0.1% | +$20.3K | 1.87% | 20 |
|
|
2021
Q2 | $13.7M | Buy |
350,819
+8,570
| +3% | +$333K | 1.71% | 25 |
|
|
2021
Q1 | $12.4M | Buy |
342,249
+51,372
| +18% | +$1.82M | 1.8% | 23 |
|
|
2020
Q4 | $10.7M | Buy |
290,877
+2,025
| +0.7% | +$74.3K | 1.67% | 23 |
|
|
2020
Q3 | $10.1M | Buy |
288,852
+12,541
| +5% | +$440K | 1.78% | 21 |
|
|
2020
Q2 | $8.57M | Buy |
276,311
+1,959
| +0.7% | +$66.6K | 1.61% | 24 |
|
|
2020
Q1 | $8.5M | Buy |
274,352
+21,179
| +8% | +$722K | 1.88% | 20 |
|
|
2019
Q4 | $9.41M | Buy |
253,173
+12,086
| +5% | +$430K | 1.62% | 22 |
|
|
2019
Q3 | $8.22M | Buy |
241,087
+33,675
| +16% | +$1.22M | 1.54% | 23 |
|
|
2019
Q2 | $8.53M | Buy |
207,412
+2,272
| +1% | +$90.2K | 1.59% | 22 |
|
|
2019
Q1 | $8.27M | Sell |
205,140
-9,854
| -5% | -$395K | 1.59% | 22 |
|
|
2018
Q4 | $8.9M | Sell |
214,994
-13,295
| -6% | -$552K | 1.87% | 20 |
|
|
2018
Q3 | $9.54M | Sell |
228,289
-37,480
| -14% | -$1.44M | 1.66% | 23 |
|
|
2018
Q2 | $9.15M | Sell |
265,769
-322
| -0.1% | -$11K | 1.76% | 24 |
|
|
2018
Q1 | $8.96M | Sell |
266,091
-558
| -0.2% | -$19.2K | 1.79% | 23 |
|
|
2017
Q4 | $9.16M | Sell |
266,649
-3,238
| -1% | -$110K | 1.79% | 20 |
|
|
2017
Q3 | $9.14M | Sell |
269,887
-1,813
| -0.7% | -$58.3K | 1.86% | 19 |
|
|
2017
Q2 | $8.66M | Buy |
271,700
+11,850
| +5% | +$374K | 1.78% | 22 |
|
|
2017
Q1 | $8.43M | Buy |
259,850
+10,516
| +4% | +$332K | 1.76% | 24 |
|
|
2016
Q4 | $8.01M | Hold |
249,334
| – | – | 1.8% | 19 |
|
|
2016
Q3 | $8.01M | Buy |
249,334
+90,767
| +57% | +$3.04M | 1.8% | 19 |
|
|
2016
Q2 | $5.3M | Sell |
158,567
-179
| -0.1% | -$5.71K | 1.22% | 35 |
|
|
2016
Q1 | $4.46M | Buy |
158,746
+136,166
| +603% | +$3.89M | 1.04% | 39 |
|
|
2015
Q4 | $692K | Buy |
22,580
+6,832
| +43% | +$215K | 0.16% | 104 |
|
|
2015
Q3 | $469K | Sell |
15,748
-3,257
| -17% | -$104K | 0.11% | 116 |
|
|
2015
Q2 | $605K | Sell |
19,005
-15
| -0.1% | -$489 | 0.14% | 97 |
|
|
2015
Q1 | $628K | Buy |
19,020
+3,387
| +22% | +$108K | 0.15% | 98 |
|
|
2014
Q4 | $462K | Sell |
15,633
-2,530
| -14% | -$72.5K | 0.13% | 93 |
|
|
2014
Q3 | $510K | Buy |
18,163
+2,108
| +13% | +$59.2K | 0.14% | 88 |
|
|
2014
Q2 | $452K | Buy |
16,055
+1,687
| +12% | +$48.1K | 0.12% | 93 |
|
|
2014
Q1 | $438K | Sell |
14,368
-527
| -4% | -$15.7K | 0.13% | 96 |
|
|
2013
Q4 | $433K | Buy |
14,895
+211
| +1% | +$6.14K | 0.12% | 98 |
|
|
2013
Q3 | $400K | Hold |
14,684
| – | – | 0.13% | 99 |
|
|
2013
Q2 | $390K | Buy |
+14,684
| New | +$406K | 0.12% | 103 |
|
Other funds holding PFE
BTR Capital Management's PFE Position: Q3 2022 in Review
BTR Capital Management increased its Pfizer (PFE) stake by 2.5% in Q3 2022, buying an estimated $420K and bringing the position to 360,859 shares worth $15.8M. The position accounts for 2.46% of the portfolio, ranked #13.
BTR Capital Management first reported a position in PFE in Q2 2013 and has held it in 38 quarters since. The position peaked at $20.9M in Q4 2021. 3,085 funds tracked by Wall St. Rank hold PFE as of Q3 2022.
- BTR Capital Management held 360,859 shares of Pfizer worth $15.8M as of Q3 2022.
- BTR Capital Management bought 8,640 Pfizer shares in Q3 2022, an estimated $420K.
- Pfizer made up 2.46% of BTR Capital Management's portfolio in Q3 2022, its #13 holding.
- BTR Capital Management first reported a position in Pfizer in Q2 2013 and has held it in 38 quarters since.
- BTR Capital Management's Pfizer position peaked at $20.9M in Q4 2021.
- 3,085 funds tracked by Wall St. Rank held Pfizer as of Q3 2022.
Based on BTR Capital Management's 13F filing for Q3 2022, filed 12 Oct 2022.